Consistent with the mean of 10% weight loss observed in the naltrexone-bupropion group, which was maintained through 12 months, we observed modest improvements in the obesity-related parameters in several domains relevant to cardiometabolic risks: glycaemic control (HbA1c), lipid metabolism (LDL-C levels), liver parameters (ALT and AST levels, CAP and LS on VCTE). This evidence concerns the gene GPT and Obesity.